Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1275-1284

  Morita, Hiroshi ^a   Murata, Taku ^a   Shimizu, Kasumi ^a   Okumura, Kenya ^a   Inui, Madoka ^a   Tagawa, Toshiro ^a  

^a Mie Graduate School of Medicine   (Japan)

Author keywords

Cell cycle; Malignant melanoma; Phosphodiesterase 2A

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; CYCLIN E; ISOLEUCINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2A; THREONINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIN A; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MOUTH NEOPLASMS; MUTATION;

EID: 84874719688     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2260     Document Type: Article

References (29)

1. Thompson JF, Scolyer RA and Kefford RF: Cutaneous melanoma. Lancet 365: 687-701, 2005.
2. Beavo JA, Houslay MD and Francis SH: Cyclic nucleotide phosphodiesterase superfamily. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD (eds). CRC Press, Boca Raton, pp3-17, 2007.
3. Houslay MD: Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100, 2009.
4. Martinez SE: PDE2 structure and functions. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD (eds). CRC Press, Boca Raton, pp55-77, 2007.
5. Conti M and Beavo J: Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511, 2007.
6. Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) super¬family: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398, 2006.
7. Shimizu K, Murata T, Watanabe Y, Sato C, Morita H and Tagawa T: Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Res 29: 1119-1122, 2009.
8. Murata T, Shimizu K, Narita M, Manganiello VC and Tagawa T: Characterization of phosphodiesterase 3 in human malignant melanoma cell line. Anticancer Res 22: 3171-3174, 2002.
9. Murata T, Shimizu K, Watanabe Y, Morita H, Sekida M and Tagawa T: Expression and role of phosphodiesterase 5 in human malignant melanoma cell line. Anticancer Res 30: 355-358, 2010.
10. Kamei T, Inui M, Nakamura S, Okumura K, Goto A and Tagawa T: Interferon-? and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage and bak expression. Melanoma Res 13: 153-159, 2003.
11. Omori K and Kotera J: Overview of PDEs and their regulation. Circ Res 100: 309-327, 2007.
12. Kambayashi J, Shakur Y and Liu Y: Bench to bedside: multiple actions of the PDE3 inhibitor cilostazol. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD (eds). CRC Press, Boca Raton, pp627-648, 2007.
13. Kim DH and Lerner A: Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92: 2484-2494, 1998.
14. Morris HR, Taylor GW, Masento MS, Jermyn KA and Kay RR: Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature 328: 811-814, 1987.
15. Shimizu K, Murata T, Tagawa T, Takahashi K, Ishizawa R, Abe Y, Hosaka K and Kubohara Y: Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Cancer Res 64: 2568-2571, 2004.
16. Favot L, Keravis T, Holl V, Le Bec A and Lugnier C: VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90: 334-343, 2003.
17. Drees M, Zimmermann R and Eisenbrand G: 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53: 3058-3061, 1993.
18. Dunkern TR and Hatzelmann A: Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 274: 4812-4824, 2007.
19. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K and Loughney K: Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. Gene 191: 89-95, 1997.
20. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, Hatzelmann A, Tenor H, Schudt C, Krüll M, Schütte H, Hippenstiel S and Suttorp N: Tumor necrosis factor-a-dependent expression of phosphodiesterase 2: role in endothelial hyperper¬meability. Blood 105: 3569-3576, 2005.
21. Ahlström M, Pekkinen M, Huttunen M and Lamberg-Allardt C: Dexamathasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol 69: 267-275, 2005.
22. Gupta R, Kumar G and Kumar RS: An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity. Methods Find Exp Clin Pharmacol 27: 101-118, 2005.
23. Acin-Perez R, Russwurm M, Günnewig K, Gertz M, Zoidl G, Ramos L, Buck J, Levin LR, Rassow J, Manfredi G and Steegborn C: A phosphodiesterase 2A isoform localized to mito¬chondria regulates respiration. J Biol Chem 286: 30423-30432, 2011.
24. Netherton SJ and Maurice DH: Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67: 263-272, 2005.
25. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R: Exisulind induction of apoptosis involves guanosin 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated ß-catenin. Cancer Res 60: 3338-3342, 2000.
26. Favot L, Keravis T and Lugnier C: Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92: 634-645, 2004.
27. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942, 2004.
28. Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S and Haffty BG: Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 17: 1807-1814, 2011.
29. Johnson GE, Ivanov VN and Hei TK: Radiosensitization of melanoma cells through combined inhibition of protein regu¬lations of cell survival. Apoptosis 13: 790-802, 2008.